Lumie Benard

Lumie Benard

Auto-generated profile, based on publicly available information

Lumie Benard

Albert Einstein College of Medicine/Montefiore Medical Center, Department of Cell Biology, Bronx, NY 1

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LCLuis A. Carvajal
Luis A. Carvajal
DNDaniela Ben Neriah
Daniela Ben Neriah
ASAdrien Senecal
Adrien Senecal
LBLumie Benard
Lumie Benard
VTVictor Thiruthuvanathan
Victor Thiruthuvanathan
USUlrich Steidl
Ulrich Steidl
Dual inhibition of MDMX and MDM2 by an α-helical p53-stapled peptide (ALRN-6924) results in robust antitumor activity in acute myeloid leukemia.

2 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
UOUjunwa Cynthia Okoye-Okafor
Ujunwa Cynthia Okoye-Okafor
KJKomal K. Javarappa
Komal K. Javarappa
DTDimitrios Tsallos
Dimitrios Tsallos
JSJoseph Saad
Joseph Saad
DYDaozheng Yang
Daozheng Yang
BWBritta Will
Britta Will
Thrombocytopenia, prevalent in the majority of patients with myeloid malignancies, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), is an independent adverse prognostic factor. Azacitidine (AZA), a mainstay therapeutic agent for stem cell transplant–ineligible patients with MDS/AML, often transiently induces or further aggravates disease-associated thrombocytopenia by an unknown mechanism. Here, we uncover the critical role of an acute type-I interferon (IFN-I) signaling activation in suppressing megakaryopoiesis in AZA-mediated thrombocytopenia. We demonstrate that megakaryocytic lineage-primed progenitors present IFN-I receptors and, upon AZA exposure, engage STAT1/SOCS1-dependent downstream signaling prematurely attenuating thrombopoietin receptor (TPO-R) signaling and constraining megakaryocytic progenitor cell growth and differentiation following TPO-R stimulation. Our findings directly implicate RNA demethylation and IFN-I signal activation as a root cause for AZA-mediated thrombocytopenia and suggest mitigation of TPO-R inhibitory innate immune signaling as a suitable therapeutic strategy to support platelet production, particularly during the early phases of AZA therapy.